Skip to content
eHealthTutorial — Research Peptide Reviews
Investigational • Identity-sensitive

Modified GRF(1-29) terminology

CJC-1295 (no DAC)

“CJC-1295 no DAC” is a supplier term often used for a non-albumin-binding modified growth-hormone-releasing factor fragment. It must not inherit the human results reported for albumin-binding CJC-1295 with DAC.

Open calculator Explore the research
Generic research visual — not a commercial product
Compound typeNon-DAC GHRH/GRF analogue designation
Evidence baseAnalytical literature; no equivalent DAC trial
Regulatory contextUnapproved research designation / Identity-sensitive
Page purposeResearch and calculation

Compound calculator

CJC-1295 (no DAC) reconstitution calculator

Enter the values printed on your vial and the liquid volume you added to calculate concentration, liquid volume, and the corresponding mark on a U-100 syringe scale.

Selected peptide or compoundCJC-1295 (no DAC)
Enter the total amount printed on the vial.
mL
Enter the liquid volume added in milliliters.
You provide this amount; the calculator does not select or recommend it.
Scale reference only; confirm the markings on the physical syringe.

Your CJC-1295 (no DAC) calculation appears here

Enter the three required values to see the mathematical result.

This calculator performs arithmetic using values you enter. It does not select or recommend an amount, schedule, treatment, preparation method, or method of administration.

Research overview

What is CJC-1295 (no DAC)?

The “no DAC” designation indicates absence of the drug-affinity complex used for albumin binding in long-acting CJC-1295. The marketed shorthand is not a substitute for an exact peptide sequence and chemical characterization. Modified GRF(1-29) is a name encountered in analytical literature, but products using this label can still differ in actual identity or added modifications.

What has research examined?

An analytical study identified modified GRF(1-29) and unexpected glycine-modified variants in seized powders by comparison with reference standards, illustrating why a name alone is inadequate. By contrast, the often-cited controlled human CJC-1295 study tested a long-acting, albumin-binding analogue and measured growth-hormone and IGF-I responses for that studied substance. Those findings should not be transferred to a no-DAC vial. FDA lists CJC-1295 among substances with possible immunogenicity and peptide-impurity concerns, limited clinical data, and serious adverse-event reports including increased heart rate and systemic vasodilation.

Important limitation

The available DAC studies do not establish pharmacokinetics, benefit, safety, or preparation for a non-DAC product. Analytical confirmation of different peptides in seized materials underscores identity uncertainty. This page gives no amount, schedule, use, or combining advice.

Research references

Calculation boundary

The calculator performs concentration arithmetic only when a user enters a mass and liquid volume. It does not verify identity, formulation, purity, sterility, stability, compatibility, biological-unit equivalence, or whether reconstitution applies to a particular product. Do not convert IU or other biological units to mg without an authoritative, exact-product relationship.

For research purposes only. This page is educational and is not medical or veterinary advice or a recommendation to purchase, prepare, administer, or use any product.

Continue exploring

These pages share a research topic (Growth-hormone releasing-hormone research). A link does not mean the compounds have the same mechanism, evidence, formulation, or use.

Long-acting albumin-binding GHRH analogue CJC-1295 with DAC View research profile Tesamorelin GHRH analogue Tesamorelin View research profile
Browse the full peptide and compound library